9 results about "Mannan-binding lectin" patented technology

The invention discloses a marker combination, a kit thereof and application of the marker combination to prediction of diabetic peripheral neuropathy, the marker combination comprises human angiotensin (ANG), human vascular endothelial cell adhesion molecule 1 (VCAM1) and human mannan binding lectin serine peptide 1 (MASP1), TMT quantitative proteomics and PRM targeted proteomics are adopted, and the marker combination is used for detecting diabetic peripheral neuropathy. A technology combination strategy of an ELISA experiment is adopted, and key differential expression proteins such as MASP1, VCAM1 and ANG in serum exosomes of patients with diabetic peripheral neuropathy are systematically screened and verified. By establishing a multi-model machine learning diagnosis system based on logistic regression, a support vector machine and a naive Bayes algorithm, simple and rapid identification of diabetic peripheral neuropathy patients is realized, and a new experimental basis is provided for clarification of a molecular regulation network of diabetic peripheral neuropathy; more importantly, a rapid screening tool with clinical application potential is developed.

The present disclosure provides synthetic compositions useful as inhibitors of mannan-binding lectin-associated serine protease-2 (MASP-2), including compositions that selectively inhibit MASP-2 over thrombin, as well as methods for their production and use.

The present invention provides a double-stranded RNA used to suppress the expression of mannan-binding lectin-related serine protease 2 (MASP2) in cells, cells containing the nucleotide encoding the same, and a method for treating a disease or condition mediated by or related to MASP2 expression in a subject using the dsRNA or cells.

Provided are a double-stranded RNA for inhibiting the expression of mannan-binding lectin-associated serine protease 2 (MASP2) in a cell, a cell comprising a nucleotide encoding the same, and a method of using the dsRNA or cell to treat a disease or condition mediated or associated with the expression of MASP2 in a subject.

The present invention relates to a mannan-binding lectin modified protein ppg-rep-MBL, a DNA molecule, an expression vector, a host cell, and uses, and belongs to the field of biomedical technology. The present invention provides a mannan-binding lectin modified protein ppg-rep-MBL, whose amino acid sequence is shown in SEQ ID NO:3 and whose nucleotide sequence is shown in SEQ ID NO:4. The present invention also provides the use of the mannan-binding lectin modified protein ppg-rep-MBL in the preparation of a drug for preventing or / and treating coronavirus infection. The modified protein of the present invention does not bind to the MASP2 protein, thereby significantly weakening the activation effect on the complement lectin pathway, while retaining its binding properties with mannose, and can effectively bind to and block the infection of the new coronavirus pseudovirus and its Delta mutant strain to HEK293T-ACE2 cells, providing a candidate possibility for the protein to be designed as an inhibitor or drug for the development of a broad-spectrum anti-coronavirus infection.

The present invention relates to compounds of formula (I) as inhibitors of mannan-binding lectin-associated serine protease-2 (MASP-2), including inhibitors that selectively inhibit MASP-2 over thrombin, for use in the treatment of e.g. a thrombotic microangiopathy (TMA), a renal condition, an inflammatory reaction resulting from tissue or organ transplantation, an ischemia reperfusion injury, a complication associated with diabetes, a cardiovascular disease or disorder, an inflammatory gastrointestinal disorder, a pulmonary disorder, an ophthalmic disease or disorder, disseminated intravascular coagulation, graft-versus-host disease, veno-occlusive disease, diffuse alveolar hemorrhage, idiopathic pneumonia syndrome, capillary leak syndrome, engraftment syndrome, fluid overload, a traumatic brain injury (TBI) or a combination thereof

The present invention belongs to the field of inhibitors of cell aging, and specifically relates to the application of mannan-binding lectin in inhibiting cell aging. Application of mannan-binding lectin in inhibiting cell aging for non-therapeutic purposes. The present invention confirms for the first time that MBL is closely related to cell aging induced by oxidative stress, and can inhibit the in vitro aging of NIH-3T3 mouse embryonic fibroblasts induced by hydrogen peroxide, including inhibiting the activity of β-galactosidase associated with aging, maintaining the normal morphology of the cell nucleus under conditions of DNA damage caused by oxidative stress, inhibiting the accumulation of aging marker proteins P53 and P21, enhancing the expression level of cell longevity gene SIRT1mRNA, inhibiting cell arrest in the G1 / G0 phase, thereby enhancing the ability of cell proliferation, and reducing the level of intracellular reactive oxygen species (ROS).